Zobrazeno 1 - 10
of 550
pro vyhledávání: '"myasthenia gravis (mg)"'
Publikováno v:
Zhongguo shuxue zazhi, Vol 37, Iss 8, Pp 946-952 (2024)
Myasthenia gravis(MG) is an autoimmune disease mainly mediated by autoantibodies that disorders the transmission of excitation at the neuromuscular junction. The predominant clinical manifestation is the muscle fluctuant weakness and fatigability, an
Externí odkaz:
https://doaj.org/article/353c0badd8c242f4ba15c8e36e6f74e6
Autor:
Nai-Wen Tsai, Li-Nien Chien, Connie Hung, Amanda Kuo, Yu-Ting Chiu, Hung-Wei Lin, Li-Shan Jian, Kai-Pei Chou, Jiann-Horng Yeh
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 809-824 (2024)
Abstract Introduction Myasthenia gravis (MG) is a chronic neuromuscular disease leading to significant disease burden. This study aimed to investigate the epidemiology of MG in Taiwan. Methods A retrospective study was conducted using the Taiwan Nati
Externí odkaz:
https://doaj.org/article/d43579aa4aa1496e9c97793ad73b1e49
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
ObjectivesThe objective of this research was to generate psychometric evidence supporting the myasthenia gravis (MG) symptoms patient-reported outcome (PRO) scales as a fit-for-purpose measure of severity of core symptoms of MG and provide informatio
Externí odkaz:
https://doaj.org/article/bec1fe3766134ae297bd3459e552a7f8
Autor:
Claudia Vinciguerra, Anna D’Amico, Liliana Bevilacqua, Nicasio Rini, Maria D’Apolito, Eliana Liberatoscioli, Roberto Monastero, Paolo Barone, Filippo Brighina, Antonio Di Muzio, Vincenzo Di Stefano
Publikováno v:
Brain Sciences, Vol 14, Iss 8, p 774 (2024)
Background: Myasthenia gravis (MG) is an autoimmune disease characterized by fluctuating muscle weakness due to autoantibodies targeting neuromuscular junction proteins. Mycophenolate mofetil (MMF), an immunosuppressive therapy, has shown potential f
Externí odkaz:
https://doaj.org/article/cc08e8d94b004aa68552987fe8e483e2
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against post-synaptic proteins of the neuromuscular junction. Up to 10%–30% of patients are refractory to conventional treatments. For these patients, rituximab has been
Externí odkaz:
https://doaj.org/article/10038d2a03c94ddab95b82c8a5ec3c64
Publikováno v:
Annals of Indian Academy of Neurology, Vol 26, Iss 4, Pp 395-400 (2023)
Background: Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction, and in over 80% of cases, antibodies are identified against the nicotinic type of acetylcholine receptor (AChR) on the muscle endplate. Despite the avai
Externí odkaz:
https://doaj.org/article/68e8353f2c174bdab94c2cd2cf19cd4a
Autor:
Vinaya Bhandari, Vera Bril
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Myasthenia gravis (MG) is an autoimmune disorder characterized by autoantibodies specifically directed against proteins located within the postsynaptic membrane of the neuromuscular junction. These pathogenic autoantibodies can be reduced by therapie
Externí odkaz:
https://doaj.org/article/39d941d860e942a5aab48ba46f2534b4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/a7d60bca22164e46b9143088f7a34c15